Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash from Operations (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Cash from Operations for 9 consecutive years, with 98538000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 17.71% to 98538000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 412600000.0, a 18.67% decrease, with the full-year FY2025 number at 412600000.0, down 18.67% from a year prior.
  • Cash from Operations was 98538000.0 for Q4 2025 at Denali Therapeutics, up from 107296000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 41434000.0 in Q3 2021 to a low of 131468000.0 in Q1 2025.
  • A 5-year average of 78719500.0 and a median of 73980500.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: tumbled 48279.07% in 2021, then skyrocketed 32.31% in 2024.
  • Denali Therapeutics' Cash from Operations stood at 65494000.0 in 2021, then dropped by 10.95% to 72663000.0 in 2022, then crashed by 35.77% to 98657000.0 in 2023, then rose by 15.15% to 83715000.0 in 2024, then dropped by 17.71% to 98538000.0 in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Cash from Operations are 98538000.0 (Q4 2025), 107296000.0 (Q3 2025), and 75298000.0 (Q2 2025).